NSE · BAFNAPH
Bafna Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹27 Cr with net profit ₹0 Cr — a 0.3% net margin, versus 6.51% the period before.
Shareholding
As of 2026-09-30
- Promoter75%
- Public15.66%
- FII9.34%
6,810 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.06× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 2 · T2T. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 5.06× (₹94.77 to ₹479.95) — an unusually wide band.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #7 of 15 by market cap · medians across 14 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | ₹18,207 Cr | 26.45 | 5.01 | 18.44% | 24.95% |
| Astrazeneca Pharma India Ltd. | ₹15,934 Cr | 91.85 | 18.3 | 20.22% | 6.83% |
| Akums Drugs & Pharmaceuticals Ltd. | ₹11,568 Cr | 30.65 | 3.29 | 10.39% | 7.54% |
| Procter & Gamble Health Limited | ₹9,223 Cr | 25.89 | 13.99 | 57.72% | 25.48% |
| Gujarat Themis Biosyn Ltd. | ₹4,948 Cr | 105.91 | 6.51 | — | 25.04% |
| Jagsonpal Pharmaceuticals Ltd. | ₹1,408 Cr | 29.82 | 5.79 | 18.66% | 15.13% |
| Bafna Pharmaceuticals Ltd.(this company) | ₹1,075 Cr | 138.15 | 11.29 | 11.54% | 5.46% |
| Bajaj HealthCare Limited | ₹1,046 Cr | 17.97 | 1.88 | 10.45% | 3.14% |
| Anuh Pharma Limited | ₹817 Cr | 17.1 | 2.29 | 13.27% | 6.14% |
| Amanta Healthcare Limited | ₹758 Cr | 41.37 | 3.33 | 8.04% | 6.04% |
AI analysis
AI-generated · google/gemini-2.5-flashBafna Pharmaceuticals Ltd. (BAFNAPH) has a market capitalization of Rs 542 Cr. The company reported revenue of Rs 148.6 Cr, a decrease of 2.6%. The company's EPS stands at Rs 4.69, with a PE ratio of 197.41. Return on equity is 11.54% and return on capital employed is 10.63%.
Positives
- +Promoter holding is high at 75% as of Mar 31, 2026.
- +The debt-to-equity ratio is 0.7, indicating moderate leverage.
Negatives
- −Revenue decreased by 2.6% to Rs 148.6 Cr.
- −The trailing twelve-month PE ratio is 197.41, which is high.
- −The company is under ESM 2 surveillance according to the provided data.
- −No dividend yield was reported (0%).
Financial Performance
Bafna Pharmaceuticals Ltd. reported a revenue of Rs 148.6 Cr, which represents a -2.6% decrease from the previous period. The company's profit margin for the period was 7.37%. Quarterly revenue for Mar 2026 was Rs 42.24 Cr, with net profit at Rs 2.75 Cr for the same quarter.
Profitability & Returns
The company's an nual EPS is Rs 4.69. Bafna Pharmaceuticals Ltd. delivered a Return on Equity (ROE) of 11.54% and a Return on Capital Employed (ROCE) of 10.63%. The profit margin stood at 7.37%.
Balance Sheet
Bafna Pharmaceuticals Ltd. has a debt-to-equity ratio of 0.7. The book value per share is Rs 40.64. No dividend yield was reported.
Ownership & Pledges
As of March 31, 2026, promoter holding in Bafna Pharmaceuticals Ltd. was 75%. Institutional investors, including FIIs, held 9.34% of the shares, while public shareholding was 15.66%. There were no promoter share pledges reported for the period.
Regulatory & Surveillance
Bafna Pharmaceuticals Ltd. is currently under ESM (Enhanced Surveillance Measure) Stage 2 surveillance. This involves specific regulatory measures due to certain criteria.
Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Bafna Pharmaceuticals Ltd.share price & fundamentals